Dear distinguished guests, ladies and gentlemen,

On behalf of the organizing committee, it is my great pleasure to welcome you to the 21st Antibody Therapeutic Conference (ATC) – the 2026 Antibody Therapeutics Conference: Extended Applications of Antibodies. The conference will be held on May 26–27, 2026, at the National Biotechnology Research Park in Taipei, Taiwan.

In recent years, the field of antibody therapeutics has continued to experience remarkable growth, particularly in the treatment of cancer, immune-mediated diseases, and infectious diseases. Advances in antibody engineering have led to the rapid development of next-generation modalities, including bispecific antibodies, antibody-drug conjugates (ADCs), and T-cell–engaging therapies.

These innovative immunotherapies—ranging from checkpoint blockade and ADCs to chimeric antigen receptor T-cell (CAR-T) therapies—are transforming the landscape of modern medicine and offering new hope for patients with previously difficult-to-treat diseases.

This year, ATC will continue to showcase a broad spectrum of remarkable achievements, with a focus on the extended applications of antibodies and emerging therapeutic modalities for the treatment of human diseases. We aim to provide a platform for participants to connect, communicate, gain new knowledge, and discuss the latest advances in this rapidly evolving field.

The Taiwan Antibody Association (TAA), the organizer of ATC, was established in 2012 with the mission of facilitating research and industrial development of antibody therapeutics and related technologies in Taiwan. By hosting international conferences such as ATC, we hope to promote the exchange of ideas and foster collaborations between senior experts and young scientists from around the world.

We sincerely hope that this conference will be informative and inspiring, and that it will encourage meaningful contributions to the advancement of antibody therapeutics. Once again, we thank you for joining us and wish you a productive and enjoyable conference.